EFFICACY OF FLUNISOLIDE HFA (AEROSPAN) IN ADULT AND ADOLESCENT PATIENTS 12 YEARS AND OLDER WITH ASTHMA BY BASELINE INHALED STEROID.

被引：0
|
作者：
Greos, L.
Corren, J.
Ruiz, N.
Karafilidis, J.
机构：
来源：
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY | 2014年 / 113卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学];
学科分类号：
100102 ;
摘要：
P62
引用
收藏
页码：A42 / A42
页数：1
相关论文
共 11 条
  • [1] Evaluation of Efficacy of Flunisolide HFA (AEROSPAN) in Children 4 to 11 Years of Age: A Sub-Group Efficacy Analysis By Baseline Asthma Medication Use
    Karafilidis, John
    Ruiz, Nancy
    Martens, Alison G.
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2015, 135 (02) : AB5 - AB5
  • [2] Long-Term Safety Of Flunisolide Hfa In Adult, Adolescent And Pediatric Patients With Asthma
    Graham, L.
    Marcus, M.
    Karafilidis, J.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2015, 191
  • [3] Evaluation Of The Efficacy And Safety Of Flunisolide Hfa In Pediatric Asthma Patients 4 To 11 Years Of Age
    Newman, K.
    Karafilidis, J.
    Wheeler, W.
    Ruiz, N.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2014, 189
  • [4] Improved pulmonary function in patients with mild-to-moderate asthma treated with inhaled HFA flunisolide for 12 weeks
    Newman, K
    Corren, J
    Nelson, H
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2001, 107 (02) : S104 - S105
  • [5] A Double-Blind Placebo-Controlled, Multicenter, Cross-Over, Dose-Ranging Study to Compare the Efficacy and Safety of Albuterol Spiromax and Proair HFA in Adult and Adolescent Patients Ages 12 and Older with Persistent Asthma
    Kerwin, Edward M.
    Taveras, Herminia
    Iverson, Harald
    Wayne, Denise
    Shah, Tushar
    Lepore, Mark S.
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2013, 131 (02) : AB5 - AB5
  • [6] Efficacy and safety of inhaled budesonide delivered once or twice daily via HFA-134a in mild to moderate persistent asthma in adult patients. Comparison with budesonide CFC
    Vastagh, E
    Kuna, P
    Calistru, P
    Bogdan, MA
    RESPIRATORY MEDICINE, 2003, 97 : S20 - S28
  • [7] Albuterol in HFA propellant (ALB-HFA) 180mcg QID is comparable in safety and efficacy to albuterol in CFC propellant (ALB-CFC) 180mcg QID in adolescent and adult patients with asthma.
    Cohen, RM
    Plescow, WW
    Webb, DR
    Devorin, DJ
    Rooklin, AR
    Barnhart, FH
    Furlong, AV
    McClung, CL
    Stahl, EG
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 1999, 103 (01) : S128 - S128
  • [8] Updated guidelines (2015) for management and monitoring of adult and adolescent asthmatic patients (from 12 years and older) of the Societe de pneumologie de langue francaise (SPLF) (summary)
    Raherison, C.
    Bourdin, A.
    Bonniaud, P.
    Deslee, G.
    Garcia, G.
    Leroyer, C.
    Taille, C.
    De Blic, J.
    Dubus, J. -C.
    Tillie-Leblond, I.
    Chanez, P.
    REVUE DES MALADIES RESPIRATOIRES, 2016, 33 (04) : 271 - 278
  • [9] Updated guidelines (2015) for management and monitoring of adult and adolescent asthmatic patients (from 12 years and older) of the Societe de Pneumologie de Langue Francaise (SPLF) (Full length text)
    Raherison, C.
    Bourdin, A.
    Bonniaud, P.
    Deslee, G.
    Garcia, G.
    Leroyer, C.
    Taille, C.
    De Blic, J.
    Dubus, J-C.
    Tillie-Leblond, I.
    Chanez, P.
    REVUE DES MALADIES RESPIRATOIRES, 2016, 33 (04) : 279 - 325
  • [10] Randomized, double-blind trial evaluating the efficacy and safety of fluticasone propionate and fluticasone propionate/salmeterol delivered via multidose dry powder inhalers in patients with persistent asthma aged 12 years and older
    Raphael, Gordon
    Yiu, Gloria
    Sakov, Anat
    Liu, Siyu
    Caracta, Cynthia
    JOURNAL OF ASTHMA, 2018, 55 (06) : 640 - 650
12